Oral vitamin B6 treatment for PNPO deficiency
Part of Genetic & congenital clinical trials.
This Phase 3 study tests an oral form of vitamin B6 (P5P) to treat PNPO deficiency, a rare genetic condition that can cause seizures. It’s meant for people whose seizures are usually controlled on this treatment, to confirm the best approach going forward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed PNPO deficiency from genetic testing
- Your seizures are generally controlled with oral P5P taken multiple times per day for at least 30 days
- You are at least 2 years old
- You may join if you previously tried pyridoxine (vitamin B6) and it didn’t work, as long as you’ve been off pyridoxine for at least 24 hours
- You can give consent (or a parent/guardian can if you’re under 18)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether high doses of vitamin C are safe for people with certain red blood cell conditions: pyruvate kinase deficiency or a specific type of G6PD deficiency (Class A). The goal is to see if vitamin C can be given safely to these patients.
This study tests an oral medication (MY008211A) designed to reduce red blood cell destruction in people with paroxysmal nocturnal hemoglobinuria (PNH). The trial aims to see if the drug is safe and effective in improving anemia and lowering markers of disease activity.
This trial tests a one-time gene therapy called NGGT002 for adults with classic PKU who cannot take or do not respond well to current treatments. The goal is to see if it can safely lower blood phenylalanine levels.
This study tests whether a specific mix of large neutral amino acids (LNAAs) can help adults with classical PKU by lowering phenylalanine levels in the brain. It includes an MRI and PET scan to see how the treatment affects brain activity.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests an investigational drug called NM8074 that may help people with paroxysmal nocturnal hemoglobinuria (PNH) who still have symptoms despite being on Soliris. It aims to see if the new drug is safe and effective when added or when switching from Soliris.
Hear when a new Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.